Page 4 - Zydus Cadila

Zydus gets nod for trials of antibodies cocktail to treat Covid-19: Report

Zydus said that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies can emerge as one of the main treatments for mild Covid-19

Zydus introduces scratch code in critical drug packs to fight counterfeit

Drug firm Zydus Cadila on Friday said it has introduced a new feature in the packaging of its critical drugs to help patients ensure that the product is not fake or counterfeited

Zydus Cadila Q4 net up 73% to Rs 679 cr, total income up a marginal 3%

During Q4FY21, firm launched Virafin to treat moderate infections in adult Covid-19 patients. Its ZyCoV-D plasmid DNA vaccine is at an advanced stage of Phase-3 trials

Drugmaker Zydus Cadila's fourth quarter net profit up 73% at Rs 679 crore

Total income from operations of Rs 3,847 crore was up by 3 per cent from Rs 3,752 crore in Q4 FY20.

Zydus Cadila, Taiwan's TLC ink pact to market black fungus drug in India

Black fungus cases are on the rise in India

Zydus Cadila to sell India animal health business for Rs 2,921 crore

We are sure that ZAHL will continue to grow and strengthen its position, said Pankaj Patel

Multiples Alternate Asset Mgt-led group to buy Cadila's animal health biz

The deal is to sell one of Cadila's two businesses on a slump sale basis as a going concern, for a lump sum of Rs 2,921 cr on cash-free and debt-free basis

Covid vaccine, price and availability after May 1: All you need to know

In this podcast, we take a look at all those important updates related to coronavirus vaccine in a quick time

Covid-19: Govt waives import duty on Remdesivir injection, raw materials

Given the shortage of supplies, the Union government last week banned the export of Remdesivir

Zydus Cadila gets USFDA nod for cancer, high blood pressure treatment drug

Drug firm Zydus Cadila on Thursday said it has received final approval from the US health regulator to market Ibrutinib Capsules, used to treat certain cancers

Zydus seeks DCGI nod for add'l indication of Hep C drug in Covid-19 therapy

In a likely breakthrough, interim results indicate that PegIFN when administered early on, could help patients recover faster and avoid complications seen in advanced Covid stages

Zydus Cadila seeks approval for its repurpose Hepatitis C drug for Covid-19

Cadila's Hepatitis C drug has shown promising interim results as a treatment for Covid-19 in a late-stage trial, the drugmaker said on Monday

Zydus Cadila receives tentative nod from USFDA to market two HIV drugs

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ Ahmedabad

Zydus Cadila reduces price of generic Covid-19 drug to Rs 899 per vial

The company sells the drug under the brand name 'Remdac'

Zydus Cadila gets USFDA final nod for low blood pressure drug Droxidopa

The newly approved medication will be manufactured at the group''s formulation manufacturing facility at SEZ, Ahmedabad

Zydus Cadila's Q3 net up 41% to Rs 527 cr on strong India biz growth

US formulations business dips 4% with revenues at Rs 1,603 cr, Q3 sees Zydus file 10 additional ANDAs with US FDA, taking total filings to 410

More Covid-19 vaccine candidates get approval for clinical trials in India

As for Bharat Biotech's chimpanzee flu virus (adenovirus) based intra-nasal vaccine candidate, the SEC recommended grant of permission for phase I trials

More Covid-19 vaccine candidates get approval for clinical trials in India

As for Bharat Biotech's chimpanzee flu virus (adenovirus) based intra-nasal vaccine candidate, the SEC recommended grant of permission for phase I trials

Zydus Cadila says 'positive results' from phase 2 studies of Covid-19 drug

Drug firm Zydus Cadila on Monday said it has received positive results from phase 2(b) studies of Desidustat in Covid-19 patients conducted in Mexico.

Serum, Bharat Biotech vaccines get restricted use approval from DCGI

While the Oxford-AstraZeneca vaccine made by Serum Institute here has 70.42% efficacy, Bharat Biotech's still does not have efficacy data as trials are underway in India